EXpanding Treatment for Existing Neurological Disease (EXTEND): An Open-Label Phase II Clinical Trial of Hydroxyurea Treatment in Sickle Cell Anemia
EXpanding Treatment for Existing Neurological Disease (EXTEND): An Open-Label Phase II Clinical Trial of Hydroxyurea Treatment in Sickle Cell Anemia
Angela E Rankine-Mullings 1, MBBS, MRCPCH; Courtney R Little 2, RN, BSN; Marvin E Reid 3, MBBS, PhD; Deanne P Soares 3, MBBS, DM; Carolyn Taylor-Bryan 3, MBBS, DM; Jennifer M Knight-Madden 1, MBBS, PhD; Susan E Stuber 2, MA; Asha V Badaloo 3, PhD; Karen Aldred 1, MSc; Margaret E Wisdom-Phipps 1, RN, RM; Teresa Latham 2, MA; Russell E Ware 2, MD, PhD 1 Sickle Cell Unit, Tropical Medicine Research Institute, University of the West Indies, Kingston ,
JM
2 Division of Hematology , Cincinnati Children’s Hospital Medical Center, Cincinnati, OH,
US
3 Tropical Metabolism Research Unit, Tropical Medicine Research Institute, University of the West Indies, Kingston ,
JM